, 23 Baylor Institute for Immunology Research, Brooke Army Medical Center
, 27 Division of Immunology and Rheumatology, 26 Adaptive Biotechnologies, p.28
29 Cellular & Molecular Pathology Graduate Program ,
, 32 Immunology Program, Memorial Sloan-Kettering Cancer Center, Institut GrustaveRoussy, vol.33, p.34
Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010. ,
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006. ,
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.6, pp.610-618, 2011. ,
TNM staging in colorectal cancer: T is for T cell and M is for memory, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.6, pp.601-604, 2011. ,
The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, vol.12, issue.4, pp.298-306, 2012. ,
Cancer classification using the Immunoscore: a worldwide task force, J Transl Med, vol.10, p.205, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00780742
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours, J Pathol, vol.232, issue.2, pp.199-209, 2014. ,
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discovery, vol.1, issue.1, pp.54-67, 2011. ,
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment, J Transl Med, vol.11, p.54, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00804641
Defining the critical hurdles in cancer immunotherapy, J Transl Med, vol.9, p.214, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00691923
Immunogenic and tolerogenic cell death, Nature Reviews Immunol, vol.9, issue.5, pp.353-63, 2009. ,
DOI : 10.1038/nri2545
URL : http://europepmc.org/articles/pmc2818721?pdf=render
Immune response against dying tumor cells, Adv Immunol, vol.84, pp.131-79, 2004. ,
DOI : 10.1016/s0065-2776(04)84004-5
URL : https://hal.archives-ouvertes.fr/pasteur-01402386
Immune parameters affecting the efficacy of chemotherapeutic regimens, Nat Rev Clin Oncol, vol.8, issue.3, pp.151-60, 2011. ,
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J Exp Med, vol.202, issue.12, pp.1691-701, 2005. ,
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death, Sci Transl Med, vol.4, issue.143, pp.143-99, 2012. ,
, FDA: (US) Food and Drug Administration; Foxp3: forkhead box P3
, GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLP: Good Laboratory Practice; GM-CSF: granulocyte-macrophage colony-stimulating factor
, HLA: human leukocyte antigen; HMGB1: high mobility group box 1
, ICD: immunogenic cell death; ICH: International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
, ICR: immunologic constant of rejection, vol.2, p.3
, IEC: International Electrotechnical Commission; IFN-?:interferon gamma
, IL-6: interleukin 6; ILC: innate lymphoid cells; irAE: immune-related adverse event; IRC?: Immune Repertoire Capture?; ISO: International Organization for Standardization; ISV: in situ vaccination; ITA: immune-targeted agent; KIR: killercell immunoglobulin-like receptor
, MICA: major histocompatibility complex class I-related chain A; MICB: major histocompatibility complex class Irelated chain B; mRNA: messenger RNA; MTD: maximum tolerated dose, MHC: major histocompatibility complex; MIBBI: Minimum Information for Biological and Biomedical Investigations
, NK: natural killer; PBMC: peripheral blood mononuclear cells; PCR: polymerase chain reaction; PD: pharmacodynamics; PD-1: programmed cell death protein 1
of PD-1; PK: pharmacokinetics; qPCR: quantitative polymerase chain reaction; RNAseq: sequencing technology to sequence the repertoire of RNA transcripts in a biologic sample; RUO: research use only; sMICA: soluble major histocompatibility complex class I-related chain A; sMICB: soluble major histocompatibility complex class I ,
, TDLN: tumor-draining lymph node; TIL: tumor-infiltrating lymphocyte; TLR7: tolllike receptor 7; TLR9: toll-like receptor 9
, TNM: tumor-node-metastasis (staging)
, Treg: regulatory T cell
, TSDR: Treg cell-specific demethylated region
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death, EMBO J, vol.28, issue.5, pp.578-90, 2009. ,
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy, J Exp Med, vol.208, issue.3, pp.491-503, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00576679
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors, Nature Med, vol.15, issue.10, pp.1170-1178, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00419823
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, vol.392, issue.6671, pp.86-95, 1998. ,
Apoptosis in the pathogenesis and treatment of disease, Science, vol.267, issue.5203, pp.1456-62, 1995. ,
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice, Science, vol.334, issue.6062, pp.1573-1580, 2011. ,
Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, vol.29, issue.4, pp.482-91, 2010. ,
Immunosurveillance against cancer-associated hyperploidy, Oncotarget, vol.3, issue.11, pp.1270-1271, 2012. ,
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists, Cell Death Differ, vol.21, issue.1, pp.69-78, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02047406
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens, Autophagy, vol.8, issue.8, pp.1175-84, 2012. ,
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death, Oncoimmunol, vol.3, 2014. ,
DOI : 10.4161/onci.28518
URL : https://www.tandfonline.com/doi/pdf/10.4161/onci.28518?needAccess=true
Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med, vol.366, issue.10, pp.925-956, 2012. ,
Combining radiotherapy and cancer immunotherapy: a paradigm shift, J Natl Cancer Inst, vol.105, issue.4, pp.256-65, 2013. ,
DOI : 10.1093/jnci/djs629
URL : http://europepmc.org/articles/pmc3576324?pdf=render
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer, Clin Cancer Res, vol.11, issue.9, pp.3353-62, 2005. ,
The immunologic constant of rejection, Trends in Immunol, vol.29, issue.6, pp.256-62, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-02143596
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer, Cancer Immunol Res, vol.1, issue.6, pp.365-72, 2013. ,
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects, J Clin Invest, vol.122, issue.10, 2012. ,
DOI : 10.1172/jci61931
URL : http://www.jci.org/articles/view/61931/files/pdf
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, issue.6908, pp.734-742, 2002. ,
DOI : 10.1038/nature01112
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity, Proc Natl Acad Sci, vol.103, issue.24, pp.9190-9195, 2006. ,
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor, Nature, vol.436, issue.7054, pp.1186-90, 2005. ,
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, vol.39, issue.1, pp.49-60, 2013. ,
Innovation and opportunity for chimeric antigen receptor targeted T cells, Cytotherapy, vol.15, issue.9, pp.1046-53, 2013. ,
DOI : 10.1016/j.jcyt.2013.02.007
Adoptive immunotherapy for cancer, Immunol Rev, vol.257, issue.1, pp.14-38, 2014. ,
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, vol.3, issue.95, pp.95-73, 2011. ,
DOI : 10.1126/scitranslmed.3002842
URL : http://stm.sciencemag.org/content/3/95/95ra73.full.pdf
Chimeric antigen receptormodified T cells in chronic lymphoid leukemia, N Engl J Med, vol.365, issue.8, pp.725-758, 2011. ,
DOI : 10.1056/nejmoa1103849
URL : http://europepmc.org/articles/pmc3387277?pdf=render
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, vol.368, issue.16, pp.1509-1527, 2013. ,
DOI : 10.1056/nejmoa1215134
URL : http://europepmc.org/articles/pmc4058440?pdf=render
Biomarkers in T cell therapy clinical trials, J Transl Med, vol.9, p.138, 2011. ,
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies, Cancer Immunol Res, vol.2, issue.2, pp.112-132, 2014. ,
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, vol.6, issue.224, pp.224-249, 2014. ,
Human natural killer cells, Blood, vol.112, issue.3, pp.461-470, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00431858
Innate or adaptive immunity? The example of natural killer cells, Science, vol.331, issue.6013, pp.44-53, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00611585
Targeting natural killer cells and natural killer T cells in cancer, Nat Rev Immunol, vol.12, issue.4, pp.239-52, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00685473
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, issue.8, pp.3051-3058, 2005. ,
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer, Cytotherapy, vol.13, issue.1, pp.98-107, 2011. ,
Allogeneic natural killer cells for refractory lymphoma, Cancer Immunol Immunother, vol.59, issue.11, pp.1739-1783, 2010. ,
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition, Clin Cancer Res, vol.19, issue.14, pp.3844-55, 2013. ,
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets, Blood, vol.123, pp.3016-3042, 2014. ,
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002. ,
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy, Ann Hematol, vol.91, issue.5, pp.715-736, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00771121
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.3, pp.474-81, 2005. ,
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, issue.21, pp.3940-3947, 2003. ,
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.11, pp.1789-96, 2008. ,
FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer, Ann Oncol, vol.22, issue.6, pp.1302-1309, 2011. ,
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.7, pp.1122-1131, 2009. ,
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab, Blood, vol.113, issue.16, pp.3809-3821, 2009. ,
Targeting CD137 enhances the efficacy of cetuximab, J Clin Invest, vol.124, issue.6, pp.2668-82, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01021651
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients, Clin Cancer Res, vol.19, issue.7, pp.1858-72, 2013. ,
Cancer: Antitumour immunity gets a boost, Nature, vol.515, issue.7528, pp.496-504, 2014. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012. ,
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, vol.366, issue.26, pp.2455-65, 2012. ,
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, issue.2, pp.134-178, 2013. ,
DOI : 10.1056/nejmoa1305133
URL : http://europepmc.org/articles/pmc4126516?pdf=render
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012. ,
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS936558, ONO-4538) in a phase I trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.9002, 2014. ,
Spectroscopic study of the photofixation of SO2 on anatase TiO2 thin films and their oleophobic properties, ACS Appl Mater Interfaces, vol.4, issue.2, pp.672-681, 2012. ,
Antigen presentation and transfer between B cells and macrophages, Eur J Immunol, vol.37, issue.7, pp.1739-51, 2007. ,
DOI : 10.1002/eji.200636452
MK3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity, Clin Cancer Res, vol.20, p.20, 2014. ,
DOI : 10.1158/1078-0432.14aacriaslc-a20
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PDL1 status, J Clinical Invest, vol.32, issue.5s, p.8024, 2014. ,
,
, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), BMS-936558, vol.32, p.5010, 2014.
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.5009, 2014. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014. ,
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl JMed, vol.372, issue.4, pp.311-320, 2015. ,
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.6011, 2014. ,
Preliminary data from a multi-arm expansion study of MEDI4736, an antiPD-L1 antibody, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.5s, p.3002, 2014. ,
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, issue.7528, pp.558-62, 2014. ,
Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, issue.6165, pp.1432-1435, 2013. ,
Combination checkpoint blockade-taking melanoma immunotherapy to the next level, N Engl J Med, vol.369, issue.2, pp.187-196, 2013. ,
PD1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014. ,
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, vol.39, issue.1, pp.11-26, 2013. ,
Cancer immunology-analysis of host and tumor factors for personalized medicine, Nat Rev Clin Oncol, vol.8, issue.12, pp.711-720, 2011. ,
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, vol.39, issue.4, pp.782-95, 2013. ,
Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis, Methods, vol.70, issue.1, pp.46-58, 2014. ,
Gene-expression profiling in vaccine therapy and immunotherapy for cancer, Expert Rev Vaccines, vol.9, issue.6, pp.555-65, 2010. ,
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment, Curr Opin Immunol, vol.23, issue.2, pp.286-92, 2011. ,
Immunosequencing: applications of immune repertoire deep sequencing, Curr Opin Immunol, vol.25, issue.5, pp.646-52, 2013. ,
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Ann Oncol, vol.24, issue.6, pp.1697-703, 2013. ,
Immune modulation for cancer therapy, Br J Cancer, vol.111, issue.12, pp.2214-2223, 2014. ,
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival, Cancer, vol.116, issue.7, pp.1767-75, 2010. ,
Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3 mg/kg), J Clin Oncol Off J Am Soc Clin Oncol, vol.30, p.8575, 2012. ,
Intratumoral immunization: a new paradigm for cancer therapy, Clin Cancer Res, vol.20, p.1747, 2014. ,
BCG and cancer, N Engl J Med, vol.290, issue.26, pp.1458-69, 1974. ,
Treatment of vulvar intraepithelial neoplasia with topical imiquimod, N Engl J Med, vol.358, issue.14, pp.1465-73, 2008. ,
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.28, pp.4324-4356, 2010. ,
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study, Blood, vol.119, issue.2, pp.355-63, 2012. ,
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nature Med, vol.19, issue.3, pp.329-365, 2013. ,
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GMCSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma, J Clin Oncol, vol.31, p.9008, 2013. ,
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers, Cancer Immunol Immunother, vol.63, issue.2, pp.101-110, 2014. ,
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer, Cancer Immunol Immunother, vol.59, issue.5, pp.663-74, 2010. ,
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit, Proc Natl Acad Sci U S A, vol.105, issue.51, pp.20410-20415, 2008. ,
ELISpot for measuring human immune responses to vaccines, Expert Rev Vaccines, vol.10, issue.3, pp.299-306, 2011. ,
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories, Methods Molecular Biol, vol.792, pp.185-96, 2012. ,
Next generation sequencing: new tools in immunology and hematology, Blood Res, vol.48, issue.4, pp.242-251, 2013. ,
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma, Clin Cancer Res, vol.9, issue.3, pp.998-1008, 2003. ,
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer, PLoS Med, vol.2, issue.9, p.284, 2005. ,
Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients, J Transl Med, vol.11, p.242, 2013. ,
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells, Nature Med, vol.9, issue.11, pp.1377-82, 2003. ,
Diversity and recognition efficiency of T cell responses to cancer, PLoS Med, vol.1, issue.2, p.28, 2004. ,
Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses, J Immunother, vol.28, issue.4, pp.297-305, 1997. ,
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer, J Pathol, vol.231, issue.4, pp.433-473, 2013. ,
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas, J Pathol, vol.231, issue.4, pp.424-456, 2013. ,
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder, N Engl J Med, vol.325, issue.17, pp.1205-1214, 1991. ,
Trial watch: Oncolytic viruses for cancer therapy, Oncoimmunol, vol.2, issue.6, p.24612, 2013. ,
Engineering HSV-1 vectors for gene therapy, Methods Molecular Biol, 2014. ,
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT, BMC Immunol, vol.6, p.17, 2005. ,
An integrative paradigm to impart quality to correlative science, J Transl Med, vol.8, p.26, 2010. ,
Standardizing immunophenotyping for the Human Immunology Project, Nat Rev Immunol, vol.12, issue.3, pp.191-200, 2012. ,
Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples, Methods, vol.61, issue.1, pp.10-17, 2013. ,
Harmonization of immune biomarker assays for clinical studies, Sci Transl Med, vol.3, issue.108, pp.108-152, 2011. ,
A model for harmonizing flow cytometry in clinical trials, Nature Immunol, vol.11, issue.11, pp.975-983, 2010. ,
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project, Nature Biotechnol, vol.26, issue.8, pp.889-96, 2008. ,